Ken-Ichiro Matsuda1, Kaori Sakurada1, Kenji Nemoto2, Takamasa Kayama1, Yukihiko Sonoda3. 1. Department of Neurosurgery, Faculty of Medicine, Yamagata University, 2-2 Iida-Nishi, Yamagata, Yamagata, 990-9585, Japan. 2. Department of Radiation Oncology, Faculty of Medicine, Yamagata University, Yamagata, Yamagata, Japan. 3. Department of Neurosurgery, Faculty of Medicine, Yamagata University, 2-2 Iida-Nishi, Yamagata, Yamagata, 990-9585, Japan. ysonoda@med.id.yamagata-u.ac.jp.
Abstract
BACKGROUND: The optimal treatment for elderly patients with glioblastoma has not been established. METHODS: We retrospectively analyzed the safety and efficacy of hypofractionated radiotherapy (45 Gy/15 fr) combined with temozolomide (TMZ) followed by bevacizumab (BEV) salvage treatment in 18 glioblastoma patients aged > 75 years. RESULTS: All of the patients received safe hypofractionated radiotherapy and concomitant TMZ (75 mg/m2), and 14 of 18 patients received maintenance TMZ. We administered BEV to 17 of 18 patients because their Karnofsky Performance Status scores declined and/or recurrence was detected. During the follow-up period (median duration: 17.5 months, range 3-33 months), 12 patients died of their disease. While the median progression-free survival period was 2.5 months, the median overall survival period was 20 months. Adverse events (National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or 4) occurred in 5 patients. CONCLUSION: Hypofractionated radiotherapy combined with TMZ and BEV salvage treatment was found to be safe and effective in glioblastoma patients aged > 75 years.
BACKGROUND: The optimal treatment for elderly patients with glioblastoma has not been established. METHODS: We retrospectively analyzed the safety and efficacy of hypofractionated radiotherapy (45 Gy/15 fr) combined with temozolomide (TMZ) followed by bevacizumab (BEV) salvage treatment in 18 glioblastomapatients aged > 75 years. RESULTS: All of the patients received safe hypofractionated radiotherapy and concomitant TMZ (75 mg/m2), and 14 of 18 patients received maintenance TMZ. We administered BEV to 17 of 18 patients because their Karnofsky Performance Status scores declined and/or recurrence was detected. During the follow-up period (median duration: 17.5 months, range 3-33 months), 12 patients died of their disease. While the median progression-free survival period was 2.5 months, the median overall survival period was 20 months. Adverse events (National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or 4) occurred in 5 patients. CONCLUSION: Hypofractionated radiotherapy combined with TMZ and BEV salvage treatment was found to be safe and effective in glioblastomapatients aged > 75 years.
Authors: James R Perry; Normand Laperriere; Christopher J O'Callaghan; Alba A Brandes; Johan Menten; Claire Phillips; Michael Fay; Ryo Nishikawa; J Gregory Cairncross; Wilson Roa; David Osoba; John P Rossiter; Arjun Sahgal; Hal Hirte; Florence Laigle-Donadey; Enrico Franceschi; Olivier Chinot; Vassilis Golfinopoulos; Laura Fariselli; Antje Wick; Loic Feuvret; Michael Back; Michael Tills; Chad Winch; Brigitta G Baumert; Wolfgang Wick; Keyue Ding; Warren P Mason Journal: N Engl J Med Date: 2017-03-16 Impact factor: 91.245
Authors: Jing Li; Meihua Wang; Minhee Won; Edward G Shaw; Christopher Coughlin; Walter J Curran; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-01 Impact factor: 7.038
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth Journal: J Clin Oncol Date: 2004-03-29 Impact factor: 44.544
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: H-G Wirsching; G Tabatabai; U Roelcke; A F Hottinger; F Jörger; A Schmid; L Plasswilm; D Schrimpf; C Mancao; D Capper; K Conen; T Hundsberger; F Caparrotti; R von Moos; C Riklin; J Felsberg; P Roth; D T W Jones; S Pfister; E J Rushing; L Abrey; G Reifenberger; L Held; A von Deimling; A Ochsenbein; M Weller Journal: Ann Oncol Date: 2018-06-01 Impact factor: 32.976
Authors: Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller Journal: Lancet Oncol Date: 2012-05-10 Impact factor: 41.316